#China #Shanghai #KHB #Polaris V150 #Immunoassay Analyzer

KHB Unveils the Polaris V150 Immunoassay Analyzer at MEDICA 2025

Shanghai Kehua Bio-engineering Co., Ltd. (KHB) presented its newest compact chemiluminescence platform, the Polaris V150, during MEDICA 2025, one of the largest global medical industry events. This cutting-edge automatic chemiluminescent immunoassay analyzer epitomizes KHB's commitment to innovative solutions in automated diagnostics.

Designed for Versatility

The Polaris V150 is tailored for small and medium laboratories and serves urgent testing in large hospitals and independent labs. With a footprint of only 0.36 m², it delivers remarkable efficiency and accuracy, making it a versatile choice for various testing environments. The analyzer performs an impressive 150 tests per hour, ensuring high operational efficiency, even in space-constrained facilities.

With its continuous sample input capability for reagents and reaction cuvettes, along with a STAT function that prioritizes urgent samples, the Polaris V150 supports rapid clinical decision-making. The system includes 40 sample positions and works with serum and plasma, offering automatic dilution and comprehensive detection of liquid levels, sediment, and collision protection to enhance reliability.

High Precision with Advanced Technology

Equipped with the powerful ALP–AMPPD chemiluminescence system, the Polaris V150 provides exceptional accuracy and repeatability (CV < 3%). The reagent kits are designed as “all-in-one”, including QR-coded calibrators and a primary calibration curve, ensuring a standardized process and simplifying reagent management.

KHB’s comprehensive test menu features more than 60 tests across 10 major disease panels, covering a wide range of routine laboratory diagnostic needs. Tests include tumor markers, cardiac markers, thyroid function markers, sex hormones, infectious diseases, inflammation, glycometabolism, anemia, bone metabolism, and more.

Intelligent Design Enhancing User Experience

Beyond analytical performance, the Polaris V150 boasts an intelligent system design that increases laboratory usability. The platform enables real-time monitoring of reagent and consumable statuses, giving laboratories complete insight into their operational readiness. Its intuitive user interface and built-in touchscreen facilitate ease of navigation and operation, minimizing training requirements and enhancing the overall user experience.

To ensure continuous and quality operation, the analyzer features built-in reagent cooling for 24 hours (2-8 °C) for up to 12 positions, guaranteeing their optimal stability. Functions like remote monitoring and automated maintenance reduce downtime and simplify servicing procedures, allowing laboratories to maintain high operational continuity.

A Highlight at MEDICA 2025

The Polaris V150 was one of the key exhibits at KHB's booth at MEDICA 2025, attracting attention from global partners seeking compact yet high-performing immunotesting solutions. Live demonstrations and technical consultations provided visitors with a comprehensive overview of the device’s capabilities and usability in both routine and urgent laboratory operations.

"The interest we've seen at MEDICA underlines the strong demand for compact, high-quality chemiluminescence systems like the Polaris V150," remarked a product manager at KHB. "We are excited to present this innovation to international partners and support laboratories worldwide with effective immunotesting solutions."

About KHB

Shanghai Kehua Bio-engineering Co., Ltd. (KHB, stock code 002022.SZ) is a leader in in vitro diagnostics, offering a complete portfolio of medical diagnostic products focused on immunodiagnostics, biochemical diagnostics, molecular diagnostics, and point-of-care testing (POCT). Since its establishment in 1981, KHB has evolved into a high-tech enterprise merging research and development with manufacturing and business operations. The company was listed on the Shenzhen Stock Exchange (SZSE) in 2004.

For more information, visit KHB’s official website and their profiles on LinkedIn, Facebook, and Twitter.